Tags

Type your tag names separated by a space and hit enter

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis.
Biologics 2014; 8:169-82B

Abstract

Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of skin disease and up to 30% have joint involvement. Standard therapies for psoriasis include topical medications, phototherapy, and both oral systemic and biological therapies whereas therapies for psoriatic arthritis include nonsteroidal anti-inflammatory drugs followed by disease modifying antirheumatic drugs and/or tumor necrosis factor (TNF)-α inhibitors and interleukin-12/23p40 inhibitors. Treatment of both diseases is typically driven by disease severity. In the past decade, major advances in the understanding of the immunopathogenesis of psoriasis and psoriatic arthritis have led to the development of numerous biological therapies, which have revolutionized the treatment for moderate to severe plaque psoriasis and psoriatic arthritis. Anti-TNF-α agents are currently considered as first line biological therapies for the treatment of moderate to severe psoriasis and psoriatic arthritis. Currently approved anti-TNF-α agents include etanercept, adalimumab, and infliximab for psoriasis and psoriatic arthritis as well as golimumab and certolizumab for psoriatic arthritis. In this article, we aim to evaluate the long term safety and efficacy of etanercept in psoriasis and psoriatic arthritis.

Authors+Show Affiliations

Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA.Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA.Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24790410

Citation

Kivelevitch, Dario, et al. "Long Term Efficacy and Safety of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis." Biologics : Targets & Therapy, vol. 8, 2014, pp. 169-82.
Kivelevitch D, Mansouri B, Menter A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics. 2014;8:169-82.
Kivelevitch, D., Mansouri, B., & Menter, A. (2014). Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics : Targets & Therapy, 8, pp. 169-82. doi:10.2147/BTT.S41481.
Kivelevitch D, Mansouri B, Menter A. Long Term Efficacy and Safety of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis. Biologics. 2014;8:169-82. PubMed PMID: 24790410.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. AU - Kivelevitch,Dario, AU - Mansouri,Bobbak, AU - Menter,Alan, Y1 - 2014/04/17/ PY - 2014/5/3/entrez PY - 2014/5/3/pubmed PY - 2014/5/3/medline KW - biological therapy KW - etanercept KW - psoriasis KW - psoriatic arthritis KW - safety KW - tumor necrosis factor SP - 169 EP - 82 JF - Biologics : targets & therapy JO - Biologics VL - 8 N2 - Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of skin disease and up to 30% have joint involvement. Standard therapies for psoriasis include topical medications, phototherapy, and both oral systemic and biological therapies whereas therapies for psoriatic arthritis include nonsteroidal anti-inflammatory drugs followed by disease modifying antirheumatic drugs and/or tumor necrosis factor (TNF)-α inhibitors and interleukin-12/23p40 inhibitors. Treatment of both diseases is typically driven by disease severity. In the past decade, major advances in the understanding of the immunopathogenesis of psoriasis and psoriatic arthritis have led to the development of numerous biological therapies, which have revolutionized the treatment for moderate to severe plaque psoriasis and psoriatic arthritis. Anti-TNF-α agents are currently considered as first line biological therapies for the treatment of moderate to severe psoriasis and psoriatic arthritis. Currently approved anti-TNF-α agents include etanercept, adalimumab, and infliximab for psoriasis and psoriatic arthritis as well as golimumab and certolizumab for psoriatic arthritis. In this article, we aim to evaluate the long term safety and efficacy of etanercept in psoriasis and psoriatic arthritis. SN - 1177-5475 UR - https://www.unboundmedicine.com/medline/citation/24790410/Long_term_efficacy_and_safety_of_etanercept_in_the_treatment_of_psoriasis_and_psoriatic_arthritis_ L2 - https://dx.doi.org/10.2147/BTT.S41481 DB - PRIME DP - Unbound Medicine ER -